Sengenics, a genomics and proteomics-based research and diagnostics services company and Raybiotech, a leading USA-based global provider of ELISA and multiplex protein detection technologies, today announced that they have entered into a commercial partnership to co-brand Sengenics™ flagship protein array platform, Immunome™.
Sengenics Commercial Director, Matthew Rawlings, said, “The Raybiotech-Sengenics relationship is a very exciting commercial development to enhance Immunome™’s overall market potential. Sengenics will leverage Raybiotech’s worldwide commercial expertise in proteomics with the unique features of the Immunome™ protein array, namely, the world’s only protein array platform with 100% correctly folded, full-length and functionally validated proteins. Our aim working together will be to provide mutual customers the ability to use this technology for a wide variety of proteomics applications including autoimmune and cancer biomarker discovery; measuring and monitoring global immune response to drugs; as well as carrying out on-array kinase inhibitor drug assays.”
Raybiotech currently has over 60 distributors in more than 40 countries globally, and has established a very strong presence in the United States, Europe and China. As part of the partnership, Sengenics and Raybiotech will focus on dual-branding, marketing and distribution strategies for Immunome™ protein arrays and associated services.
A fundamental differentiating factor of Immunome™ protein arrays is that proteins are never allowed to dry out, ensuring that they maintain the correct conformation and hence remain functional. For this reason Immunome™ protein arrays are shipped on dry ice from multiple global locations. To simplify shipping logistics, Sengenics and Raybiotech will hold stock of Immunome™ protein arrays in five locations: Arizona and Georgia, Guangzhou, Brunei and Singapore.
Sengenics is a genomics and proteomics-based research and diagnostics company, with a range of patented technologies and products that are marketed to pharmaceutical companies, scientists and hospitals. Its flagship technology is the patented Immunome™ auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996. It also has additional patented and proprietary products for Human diseases that use the ThalaSURE™ and Genoverse™ brand names.
Related news link: http://www.prweb.com/releases/2016/04/prweb13352059.htm